Profund Advisors LLC Sells 4,622 Shares of Twist Bioscience Corporation $TWST

Profund Advisors LLC trimmed its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 22.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,131 shares of the company’s stock after selling 4,622 shares during the quarter. Profund Advisors LLC’s holdings in Twist Bioscience were worth $593,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after purchasing an additional 302 shares during the last quarter. Bayforest Capital Ltd grew its position in Twist Bioscience by 49.3% in the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock worth $191,000 after purchasing an additional 1,604 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in Twist Bioscience by 8.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company’s stock valued at $222,000 after buying an additional 469 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in Twist Bioscience in the 1st quarter valued at about $228,000. Finally, Xponance Inc. lifted its position in shares of Twist Bioscience by 22.0% during the 1st quarter. Xponance Inc. now owns 5,953 shares of the company’s stock worth $234,000 after buying an additional 1,072 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages recently commented on TWST. Barclays dropped their price target on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, October 2nd. Evercore ISI lowered their target price on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday, October 8th. Cowen restated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Finally, Stephens began coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective on the stock. Ten research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.80.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CAO Robert F. Werner sold 1,016 shares of the stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $31.44, for a total transaction of $31,943.04. Following the sale, the chief accounting officer owned 51,030 shares in the company, valued at $1,604,383.20. This represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Emily M. Leproust sold 4,887 shares of Twist Bioscience stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $32.08, for a total value of $156,774.96. Following the completion of the transaction, the chief executive officer owned 733,922 shares of the company’s stock, valued at approximately $23,544,217.76. This trade represents a 0.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 122,865 shares of company stock worth $3,879,926. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $31.87 on Thursday. The firm’s 50 day moving average is $29.63 and its 200 day moving average is $31.50. The stock has a market capitalization of $1.92 billion, a P/E ratio of -21.98 and a beta of 2.43. Twist Bioscience Corporation has a 12 month low of $24.07 and a 12 month high of $55.33. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.